ClinicalTrials.gg
RecruitingNCT06066645Updated Jun 2, 2026

Travoprost Intraocular Implant + iStent Infinite

A Phase 4 interventional study of Travoprost Intraocular Implant and iStent infinite in Glaucoma, Open-Angle, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Glaukos Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.

Planned enrollment
15th of 38
150 · median 111
Started
2023
with 2 others
Phase 4
12 of 43
2 open now
Registered
36th of 43
by date

Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 15th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 in phase 4, and was the 36th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, or all of them as a file.
02

Study summary

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of open-angle glaucoma or ocular hypertension
  • qualifying IOP in the study eye

Exclusion criteria

Exclusion Criteria:

  • unmedicated (washed out) IOP of >36 mmHg in the study eye
  • to travoprost or any other components of the travoprost intraocular implant
  • vertical cup/disc ratio > 0.8 in the study eye
  • best spectacle corrected visual acuity of worse than 20/80 in either eye
  • any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    iDose TR

    Travoprost Intraocular Implant in subjects who had successful iStent infinite placement

    Drug: Travoprost Intraocular Implant · Device: iStent infinite

  • Active comparator
    iDose TR alone

    Travoprost Intraocular Implant

    Drug: Travoprost Intraocular Implant · Other: Sham procedure

Interventions

  • anchored intracameral implant containing travoprost

    Also known as: iDose TR

  • DeviceiStent infinite

    Successful iStent infinite surgery

  • OtherSham procedure

    Sham procedure (to mimic placement of an iStent infinite)

06

What researchers measure

Primary outcomes

  1. change from baseline in mean diurnal intraocular pressure (IOP)

    mean diurnal IOP at the 3 month visit minus mean diurnal IOP at baseline

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Glaukos Clinical Study Site
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2027, 44 months after the start.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Sep 14, 2023
Primary completionEst.
May 2027
CompletionEst.
Feb 2028
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06066645
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Sep 14, 2023
Primary completion
May 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jun 2, 2026

Study contacts

Study Director
Contact
idoseclinical@glaukos.com
949-739-8749
Study Manager
Contact
idoseclinical@glaukos.com
949-739-8749
Study Director
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion